Friday, July 31, 2015 10:19:47 PM
Gerald Finken revamping his linkedin profile:
------------------
Gerald Finken:
Summary
My passion for the practice of pharmacy began immediately after I graduated from pharmacy school and learned all of the ways a pharmacist can positively influence a patient's life. For over 33 years, this passion and drive has motivated me to bring the practice of pharmacy into the clinical research sector. I have always challenged traditional clinical trial models and through new processes, innovative study designs, and patient counseling services, I have been able to revolutionize the way patients receive and take their medications in clinical trials.
With the mission of making a difference in the clinical supplies sector, I founded CSM in 1997 and grew the company from a one-person consulting operation, to a multi-million dollar organization with multiple locations and 100+ employees. In 2001, I created and launched the On-Demand packaging and labeling platform, an industry breakthrough enabling a flexible clinical supply chain to keep pace with breakthrough therapies, diagnostics, and technology by delivering patient-centric medication.
While working with sponsor companies and seeing first-hand the struggle of getting FDA approval, I launched CTRP® (Clinical Trials Research Pharmacist) services as a division of CSM. By piloting this services through CSM, we were able to prove that pharmacists counseling patients in clinical trials can improve compliance, adherence, retention, and more importantly, the overall quality of the studies. In 2014, I rebranded and re-launched the CTRP® service through Center Point Clinical Services, LLC.
Both Center Point and CSM are re-defining the way our industry conducts clinical trials with the overall strategy of finding innovative solutions to help companies decrease timelines, improve study outcomes, and reduce costs while improving the strategic quality in all aspects of patient-centric medication and care.
Experience:
CEO & Founder
Center Point Clinical Services LLC
July 2013 – Present (2 years 2 months)
At Center Point, we focus on patient engagement, providing a groundbreaking Clinical Trials Research Pharmacist (CTRP®) service, in which patients enrolled in clinical trials are paired with one of our highly trained pharmacists. Giving patients access to professional counseling and education leads to an optimal clinical trial experience, which dramatically increases patient satisfaction, retention, and compliance.
President, CEO & Founder
CSM
January 1997 – Present (18 years 8 months)Fargo, North Dakota Area,
At CSM, we help companies overcome complex clinical supply challenges such as limited drug supply, short timelines and study complexity. Offering a blend of unique and innovative services, such as On-Demand Packaging and Labeling and Direct-to-Patient, our clients are able to reduce supply costs, shorten timelines, and improve study outcomes.
(Open)1 organization
(Open)1 honor or award
Staff Pharmacist
Veterans Administration Hospital
June 1995 – May 1997 (2 years)Fargo, North Dakota Area
Independent Consultant
CSM
May 1995 – December 1996 (1 year 8 months)Fargo, North Dakota Area
Director, Clinical Supply Services
PRACS Institute
March 1993 – May 1995 (2 years 3 months)Fargo, North Dakota Area
Manager, Clinical Investigational Drug Management
Bristol-Myers Squibb
June 1982 – August 1993 (11 years 3 months)Princeton, NJ
https://www.linkedin.com/pub/gerald-finken/5/190/957
Tina Schlecht:
https://www.linkedin.com/pub/tina-schlecht/2a/409/397
------------------------------------------------
Interesting that there is no mention from Peregrine (yet) about the lawsuits vs CSM and access to all the full depositions in their entirety are being blocked.... we shall see...
This was from a previous post... and original thoughts...
....................................................
IMO these two Finken and Schlecht had something to do with the outcome of the PPHM PII NSCLC clinical trial. I did some research a while back and found these patents.
SYSTEM AND METHOD FOR LABELING TRIAL STUDY MATERIALS
http://www.patentbuddy.com/Patent/20140237950
Kristina Schlecht related to Tina Schlecht who is President of Center Point ??!! and also... ex-CSM
Vice President, Retention and Compliance Services
CSM
2003 – 2006 (3 years)
Director, Pharmaceutical Care Services
CSM
2002 – 2003 (1 year)
Director, Business Development
CSM
2000 – 2002 (2 years)
https://www.linkedin.com/pub/tina-schlecht/2a/409/397
-----------
whom is also related to Shannon Schlecht and Sheila Schlecht and oh my... the puzzle pieces just keep in piling on
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM